Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
Revolution Medicines, Inc.
Turning Point Therapeutics, Inc.
Revolution Medicines, Inc.
Second Life Therapeutics
Novartis
Revolution Medicines, Inc.
Hoffmann-La Roche
Hoffmann-La Roche
Novartis
Merck Sharp & Dohme LLC